Newcastle Confidence in Concept 2018
Lead Research Organisation:
Newcastle University
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding
Organisations
Publications
Cartwright T
(2022)
Dissecting the roles of Haspin and VRK1 in histone H3 phosphorylation during mitosis
in Scientific Reports
Barker F
(2022)
Effects of nicotinamide adenine dinucleotide precursors on measures of physical performance and physical frailty: A systematic review
in JCSM Clinical Reports
Maney NJ
(2021)
Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis.
in Arthritis & rheumatology (Hoboken, N.J.)
Cartwright TN
(2022)
Robustness of NanoBiT luciferase complementation technology in the presence of widely used kinase inhibitors.
in SLAS discovery : advancing life sciences R & D
Hodgson K
(2024)
Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone.
in EBioMedicine
Naseem R
(2021)
Strategies for Enhancing Polyester-Based Materials for Bone Fixation Applications.
in Molecules (Basel, Switzerland)
| Description | Clinical Research Training Fellowship to Dr Amaani Hussain |
| Amount | £271,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2024 |
| End | 02/2027 |
| Description | GlycoScore: A non-invasive test for prostate cancer |
| Amount | £49,655 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Department | Northern Accelerator |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2020 |
| Description | GlycoScore: Superior prostate cancer diagnosis using a simple blood test |
| Amount | £150,000 (GBP) |
| Funding ID | NIHR202523 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 02/2022 |
| Description | GlycoScore: a new non-invasive blood test for prostate cancer |
| Amount | £50,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2020 |
| Description | GlycoScore: a novel blood test for prostate cancer |
| Amount | £150,000 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| Description | GlycoScore: a superior blood test to diagnose prostate cancer |
| Amount | £209,981 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| Description | Newcastle Confidence in Concept - Care Pathway analysis and further validation for GlycoScore: a novel blood test for prostate cancer |
| Amount | £66,149 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2021 |
| End | 03/2022 |
| Description | Personalised biologic treatment of psoriasis through biomarker integration and Artificial Intelligence-enabled mechanistic modelling of psoriatic plaque resolution |
| Amount | £150,000 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2023 |
| End | 03/2026 |
| Description | Senior Investigator award |
| Amount | £80,000 (GBP) |
| Funding ID | NIHR205039 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 01/2027 |
| Description | Unlocking the power of sugars to develop new therapies for prostate cancer bone metastasis |
| Amount | £498,765 (GBP) |
| Organisation | Prostate Cancer Research Centre (PCRC) |
| Sector | Private |
| Country | United Kingdom |
| Start | 12/2022 |
| End | 12/2025 |
| Title | Prostate cancer biomarkers |
| Description | A kit for diagnosing prostate cancer or determining the risk of developing prostate cancer in a subject, comprising (i) a detectably labelled agent that specifically binds to ST6GAL1 protein; and (ii) one or more of: (a) a detectably labelled agent that specifically binds GALNT7 protein; and (b) a detectably labelled protein that specifically binds to FUT8. An assay device for diagnosing prostate cancer or determining the risk of developing prostate cancer in a subject is also disclosed; the device comprising a surface with at least two detectably labelled agents located thereon, wherein the at least two detectably labelled agents are as define above. The kit or assay device may comprise a plurality of distinct detectably labelled agents that specifically independently bind to GALNT7, ST6GAL1 and GCNT1; or ST6GAL1, GCNT1 and FUT8. The kit or assay may further comprise a detectably labelled agent which binds to Prostate-Specific Antigen (PSA) protein. The kit may further comprise one or more control samples or references; and/or one or more reagents for detecting the detectably labelled agent(s). The surface may be a continuous surface, particularly a surface comprising a lateral flow surface, dot plot surface, dipstick surface or surface suitable for plasmon resonance. |
| IP Reference | GB2595425 |
| Protection | Patent granted |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | The present invention provides novel biomarkers for prostate cancer. Methods for diagnosing prostate cancer or the risk of developing prostate cancer, or for monitoring prostate cancer progression (including prostate cancer relapse) and methods for treatment of prostate cancer are also provided. The invention also provides methods for determining the therapeutic effect of appropriate treatment regimens for prostate cancer or determining a subject's compliance or adherence with a prescribed treat |
| Company Name | GlycoScoreDx |
| Description | GlycoScoreDx develops new methods of testing for prostate cancer. |
| Year Established | 2020 |
| Impact | The care pathway analysis and health economic modelling proposed in this study will provide invaluable information for the design of the clinical utility study and future clinical adoption. In addition to GlycoScore, the company has an innovation team that are validating a new diagnostic for pancreatic cancer, which will be the second product in our portfolio. |
| Website | https://www.glycoscoredx.co.uk/ |
| Description | Discussions ongoing with MedechToMarket (M2M) to develop a CE marked product for our GlycoScore test |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | CiC Newcastle Project - GlycoScore: Validation of a non-invasive diagnostic test to distinguish benign and aggressive prostate cancer Newcastle CiC Project Team are working with M2M to develop a CE marked product for our GlycoScore test. At present, we are currently finalising investment to enable us to test 400 freshly collected blood samples from prostate cancer patients. This will take approximately two years. |
| Year(s) Of Engagement Activity | 2023 |
| Description | GlycoScore blood test highlighted via local ITV news |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Presented by the CiC Newcastle Project team for 'GlycoScore: Validation of a non-invasive diagnostic test to distinguish benign and aggressive prostate cancer'. The team raised awareness through the media on the importance of early diagnosis and enabling early treatment. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.itv.com/news/tyne-tees/2023-04-10/could-a-blood-test-diagnose-early-stage-prostate-cance... |
| Description | Ongoing discussions with Biorad to develop custom antibody pairs for each of our GlycoScore biomarkers |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Newcastle CiC Project - GlycoScore: Validation of a non-invasive diagnostic test to distinguish benign and aggressive prostate cancer The Project Team have been working with Biorad to develop custom antibody pairs for each of our GlycoScore biomarkers. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Presentation to International Sarcopenia Translational Research Conference June 2021 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Communications to the International Sarcopenia Translational Research Conference 10-11 June 2021 (Virtual) - Study in Novel Neuro-Muscular Imaging Biomarkers for Motor Outcome in Stroke (Sinonims). |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.jfsf.eu/Article.php?AID=v06i03_163 |
| Description | Utilisation of media to promote the Newcastle CiC Project 'GlycoScore: Validation of a non-invasive diagnostic test to distinguish benign and aggressive prostate cancer' |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Utilisation of local ITV news channel to promote and update the audience on Newcastle CiC Project 'GlycoScore: Validation of a non-invasive diagnostic test to distinguish benign and aggressive prostate cancer' This helped inform the public on the importance of the research and early diagnosis of prostate cancer. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.itv.com/watch/news/inside-the-newcastle-landmark-leading-scientific-research-and-educati... |